Mepolizumab
Based on 1 Customer Validation
Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.4%
- CAS No.: 196078-29-2
- 분자량:146.24 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-P9926
DupilumabIL-4Rα Inhibitor -
HY-P9949
ReslizumabIL-5 Antagonist mAb -
HY-P9924
IxekizumabIL-17A Antagonist -
HY-P99486
BriakinumabAnti-IL-12/23p40 Antibody -
HY-P9909
Ustekinumab -
HY-P9927
SecukinumabIL-17A Antagonist -
HY-P9956
SiltuximabAnti-IL-6 mAb -
HY-P9925
BrodalumabAnti-IL-17R mAb -
HY-P99248
RisankizumabIL-23 IgG Monoclonal Antibody -
HY-P9945A
Mepolizumab (anti-IL5)IL-5 Inhibitor -
HY-P9923
Benralizumabanti-IL-5Rα mAb -
HY-108810
CanakinumabAnti-IL-1β Monoclonal Antibody
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IL-5
In Vitro
Mepolizumab shows nearly linear PK after intravenous administration over a 6000-fold dose range (0.05-300 mg/kg), inhibiting eosinophil proliferation with an IC50 of 1.43 mg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Pharmacokinetic analysis of mepolizumab in cynomolgus monkeys[1]
| Route | Dose (mg/kg) | Cmax (μg/mL) | AUC0-INF_obs (μg·h/mL) | T1/2 (days) | Clobs (mL·h/kg) | Vss_obs (mL/kg) |
| i.v. | 300 | 6700 | 1405000 | 11.7 | 0.217 | 74.6 |
| i.v. | 3 | 89.1 | 14600 | 11.2 | 0.208 | 82.1 |